TY - JOUR
T1 - Pronociceptive roles of schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy
AU - Koyanagi, Madoka
AU - Imai, Satoshi
AU - Matsumoto, Mayuna
AU - Iguma, Yoko
AU - Kawaguchi-Sakita, Nobuko
AU - Kotake, Takeshi
AU - Iwamitsu, Yuki
AU - Ntogwa, Mpumelelo
AU - Hiraiwa, Ren
AU - Nagayasu, Kazuki
AU - Saigo, Mamiko
AU - Ogihara, Takashi
AU - Yonezawa, Atsushi
AU - Omura, Tomohiro
AU - Nakagawa, Shunsaku
AU - Nakagawa, Takayuki
AU - Matsubara, Kazuo
N1 - Funding Information:
The authors thank BORN (Breast Oncology Research Network) BioBank, and all the participants in this study. This work was supported in part by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science [JSPS; Grants-in-Aid for Scientific Research (C) to S. Imai (17K08445), Scientific Research (B) to T. Nakagawa (17H04008, 20H03390), Challenging Exploratory Research to T. Nakagawa (17K19722), Scientific Research on Innovative Area “Thermal Biology” to T. Nakagawa (18H04696), “Integrated Bio-metal Science” to T. Nakagawa (20H05506) and Grant-in-Aid for JSPS Fellows to M. Koyanagi (18J21240)] and by grants from Smoking Research Foundation to S. Imai.
Funding Information:
M. Koyanagi reports grants from Japan Society for the Promotion of Science during the conduct of the study. S. Imai reports grants from Japan Society for the Promotion of Science and Smoking Research Foundation during the conduct of the study. No disclosures were reported by the other authors.
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/4
Y1 - 2021/4
N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting side effect of taxanes such as paclitaxel and docetaxel. Despite the high medical needs, insufficient understanding of the complex mechanism underlying CIPN pathogenesis precludes any endorsed causal therapy to prevent or relieve CIPN. In this study, we report that elevation of plasma galectin-3 level is a pathologic change common to both patients with taxane-treated breast cancer with CIPN and a mouse model of taxane-related CIPN. Following multiple intraperitoneal injections of paclitaxel in mice, galectin-3 levels were elevated in Schwann cells within the sciatic nerve but not in other peripheral organs or cells expressing galectin-3. Consistent with this, paclitaxel treatment of primary cultures of rat Schwann cells induced upregulation and secretion of galectin-3. In vitro migration assays revealed that recombinant galectin-3 induced a chemotactic response of the murine macrophage cell lineRAW264.7. In addition, perineural administration of galectin-3 to the sciatic nerve of naive mice mimicked paclitaxelinduced macrophage infiltration and mechanical hypersensitivity. By contrast, chemical depletion of macrophages by clodronate liposomes suppressed paclitaxel-induced mechanical hypersensitivity despite the higher level of plasma galectin-3. Deficiency (Galectin-3-/- mice) or pharmacologic inhibition of galectin-3 inhibited paclitaxel-induced macrophage infiltration and mechanical hypersensitivity. In conclusion, we propose that Schwann cell- derived galectin-3 plays a pronociceptive role via macrophage infiltration in the pathogenesis of taxane-induced peripheral neuropathy. Therapies targeting this phenomenon, which is common to patients with CIPN and mouse models, represent a novel approach to suppress taxane-related CIPN.
AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting side effect of taxanes such as paclitaxel and docetaxel. Despite the high medical needs, insufficient understanding of the complex mechanism underlying CIPN pathogenesis precludes any endorsed causal therapy to prevent or relieve CIPN. In this study, we report that elevation of plasma galectin-3 level is a pathologic change common to both patients with taxane-treated breast cancer with CIPN and a mouse model of taxane-related CIPN. Following multiple intraperitoneal injections of paclitaxel in mice, galectin-3 levels were elevated in Schwann cells within the sciatic nerve but not in other peripheral organs or cells expressing galectin-3. Consistent with this, paclitaxel treatment of primary cultures of rat Schwann cells induced upregulation and secretion of galectin-3. In vitro migration assays revealed that recombinant galectin-3 induced a chemotactic response of the murine macrophage cell lineRAW264.7. In addition, perineural administration of galectin-3 to the sciatic nerve of naive mice mimicked paclitaxelinduced macrophage infiltration and mechanical hypersensitivity. By contrast, chemical depletion of macrophages by clodronate liposomes suppressed paclitaxel-induced mechanical hypersensitivity despite the higher level of plasma galectin-3. Deficiency (Galectin-3-/- mice) or pharmacologic inhibition of galectin-3 inhibited paclitaxel-induced macrophage infiltration and mechanical hypersensitivity. In conclusion, we propose that Schwann cell- derived galectin-3 plays a pronociceptive role via macrophage infiltration in the pathogenesis of taxane-induced peripheral neuropathy. Therapies targeting this phenomenon, which is common to patients with CIPN and mouse models, represent a novel approach to suppress taxane-related CIPN.
UR - http://www.scopus.com/inward/record.url?scp=85104857823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104857823&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-2799
DO - 10.1158/0008-5472.CAN-20-2799
M3 - Article
C2 - 33608316
AN - SCOPUS:85104857823
SN - 0008-5472
VL - 81
SP - 2207
EP - 2219
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -